Astrazeneca (AZN) Gains from Sales and Divestitures (2016 - 2026)

Astrazeneca has reported Gains from Sales and Divestitures for 11 years, with the latest figure at -$94.0 million in Q2 2026.

• On a quarterly basis, Gains from Sales and Divestitures fell 347.62% year-over-year to -$94.0 million in Q2 2026; TTM through Jun 2026 was -$209.0 million, a 27.44% decrease from a year earlier, with the FY2025 full-year figure at -$168.0 million, down 162.5% from the prior year.
• Gains from Sales and Divestitures was -$94.0 million for Q2 2026 at Astrazeneca, down from -$34.0 million in the prior quarter.
• The five-year high for Gains from Sales and Divestitures was -$10.0 million in Q1 2022, with the low at -$251.0 million in Q4 2023.
• Average Gains from Sales and Divestitures over 5 years is -$80.2 million, with a median of -$64.0 million recorded in 2024.
• The sharpest annual moves came in 2022 and 2023: Gains from Sales and Divestitures surged 96.77% in 2022, then tumbled 2390.0% in 2023.
• Over 5 years, Gains from Sales and Divestitures stood at -$88.0 million in 2022, then sank by 185.23% to -$251.0 million in 2023, then soared by 74.5% to -$64.0 million in 2024, then increased by 21.88% to -$50.0 million in 2025, then tumbled by 88.0% to -$94.0 million in 2026.
• The last three Gains from Sales and Divestitures figures came in at -$94.0 million (Q2 2026), -$34.0 million (Q1 2026), and -$50.0 million (Q4 2025), per Business Quant data.